{
}
UBS has raised its price target for Teva Pharmaceutical Industries to $30, maintaining a Buy rating, citing strong stock performance and a positive outlook for 2025 despite a lighter catalyst environment. Teva's Q3 2024 revenues increased by 15% to $4.3 billion, driven by innovative products and generics, while analysts express confidence in the company's growth potential, particularly with the development of the anti-TL1A antagonist duvakitug in partnership with Sanofi.
UBS has reiterated its buy recommendation for Sanofi, citing the stock's attractive valuation and strong underlying growth. The target price remains at €115, with a projected 2024 P/E of approximately 16 times and a yield exceeding 4%. Key events for value creation are anticipated in 2025, including a new share buyback.
UBS has reiterated its buy recommendation for Sanofi, citing the stock's attractive valuation and strong underlying growth. The target price remains at €115, with a projected 2024 PER of around 16 times and a yield exceeding 4%. The analyst emphasizes the importance of underlying growth and a new share buyback for value creation in 2025.
UBS has raised its price target for Teva Pharmaceutical Industries to $30, maintaining a Buy rating, citing strong stock performance and a positive outlook for 2025 despite a lighter catalyst environment. Teva's Q3 2024 revenues rose 15% to $4.3 billion, driven by innovative products and generics, while analysts express confidence in the company's growth potential, particularly with the development of the anti-TL1A antagonist duvakitug.
UBS has reiterated its Buy recommendation for Sanofi, citing the stock's attractive valuation and strong underlying growth, with a target price of €115. The firm expects business EPS growth in 2024 to be at least in the low single digits, supported by robust performance and a new share buyback initiative.
UBS has reiterated its Buy recommendation for Sanofi, citing the stock's attractive valuation and strong underlying growth, with a target price of €115. The firm highlights the anticipated business EPS growth in 2024 and the new share buyback as significant for value creation in 2025.
UBS has reiterated its buy recommendation for Sanofi, as reported by Cercle Finance. BOURSORAMA, acting solely as a distribution channel, emphasizes that it has not influenced the analysis, which is provided for informational purposes only and carries no contractual value. The institution maintains a conflict of interest management policy to ensure objectivity in its investment recommendations.
UBS has reiterated its buy recommendation for Sanofi, citing the stock's attractive valuation and strong underlying growth, with a target price of €115. The firm expects TCC EPS growth for 2024 to be at least in the low single digits, supported by robust business performance and a new share buyback initiative.
UBS has maintained a "Buy" rating for Sanofi, setting a target price of 115 euros. Analyst Jo Walton highlights the stock's attractiveness in the European pharmaceutical sector, noting it is trading at a significant discount compared to peers. Anticipation builds for share buyback announcements at the end of January.
Sanofi, Europe's largest pharmaceutical group, generates 70.6% of its net sales from pharmaceuticals, focusing on specialty and general medicine. Human vaccines account for 17.4%, while consumer health products make up 12%. Geographically, 43% of sales come from the U.S., with 5.5% from France and 18.6% from Europe.
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs raises teva stock target to thirty maintains buy rating
18:04 23.01.2025
ubs maintains buy rating on sanofi citing strong growth and valuation
17:23 23.01.2025
ubs maintains buy rating on sanofi citing strong growth and valuation
17:23 23.01.2025
ubs raises teva stock target to thirty maintains buy rating
17:13 23.01.2025
ubs maintains buy rating on sanofi citing strong growth and valuation
11:20 23.01.2025
ubs maintains buy rating on sanofi citing strong growth and valuation
11:20 23.01.2025
ubs maintains buy rating on sanofi amid positive market outlook
11:15 23.01.2025
ubs maintains buy rating on sanofi citing strong growth and valuation
11:15 23.01.2025
UBS maintains buy rating for Sanofi with target price of 115 euros
09:41 23.01.2025
sanofi maintains strong market position with diverse product portfolio and global reach
09:29 23.01.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: